Xizhou Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4141765/publications.pdf

Version: 2024-02-01

1478505 1372567 11 649 10 6 citations h-index g-index papers 12 12 12 1717 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Reports, 2022, 38, 110318.	6.4	17
2	DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. Molecular Therapy - Oncolytics, 2022, 24, 218-229.	4.4	2
3	A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. IScience, 2021, 24, 102699.	4.1	15
4	Synthetic DNA Delivery of an Engineered Arginase Enzyme Can Modulate Specific Immunity InÂVivo. Molecular Therapy - Methods and Clinical Development, 2020, 18, 652-663.	4.1	1
5	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical Technology, 2020, 2, 571030.	2.5	29
6	DNA-Encoded Glutamine Synthetase Enzyme as Ammonia-Lowering Therapeutic for Hyperammonemia. Nucleic Acid Therapeutics, 2020, 30, 379-391.	3.6	2
7	Immunogenicity of a DNA vaccine candidate for COVID-19. Nature Communications, 2020, 11, 2601.	12.8	514
8	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. Advanced Science, 2020, 7, 1902802.	11,2	30
9	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structureâ€Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) Tj ETQq.	l 1102 7843	3 1 14 rgBT /
10	DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight, 2019, 4, .	5.0	36
11	Abstract 1547: DNA-encoded bispecific T-cell engagers and antibodies present long-term antitumor activity., 2019,,.		0